Efficacy and Safety of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin in HIV/HCV Coinfected Patients
Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this pilot study is to evaluate efficacy and safety of addition of IL-2 to
pegylated interferon alpha 2a and ribavirin in HIV-HCV coinfected patients non-responders
after three months of standard therapy with pegylated interferon alpha 2a and ribavirin. IL-2
may enhance numbers and function of CD4 T lymphocytes and specific anti-HCV immune responses
and could participate to the control of HCV replication
Phase:
Phase 2
Details
Lead Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis